Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 26;10(3):558.
doi: 10.3390/biomedicines10030558.

Frequency and Clinical Significance of Elevated IgG4 in Rheumatoid Arthritis: A Systematic Review

Rajalingham Sakthiswary  1 , Syahrul Sazliyana Shaharir  1 , Asrul Abdul Wahab  2
Affiliations
Review

Frequency and Clinical Significance of Elevated IgG4 in Rheumatoid Arthritis: A Systematic Review

Rajalingham Sakthiswary et al. Biomedicines. .

Abstract

Immunoglobulin (Ig)G4 is a unique protein molecule and its role in autoimmune diseases remains elusive and controversial. Accumulating evidence suggests a pathogenic role of IgG4 in rheumatoid arthritis (RA). Rheumatoid factors (RF) in RA can recognize the Fc domains of IgG4 to form RF-IgG4 immune complexes that may activate the complement system leading to synovial injury. The aim of this article was to systematically review the literature from the past 2 decades to determine the frequency of elevated IgG4 and its clinical significance in RA. We comprehensively searched the Pubmed, Scopus, and Web of Science databases with the following terms: "IgG4", "rheumatoid arthritis", and "immunoglobulin G4", and scrutinized all of the relevant publications. Based on the selection criteria, 12 studies were incorporated, which involved a total of 1715 RA patients. Out of 328 subjects from three studies, the pooled frequency of elevated non-specific IgG4 was 35.98%. There was a significant positive correlation between the IgG4 levels and the RA disease activity based on DAS-28 measurements (r = 0.245-0.253) and inflammatory markers, i.e., erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels (r = 0.262-0.389). Longitudinal studies that measured the serial levels of IgG4 consistently showed a decline in the concentrations (up to 48% less than baseline) with disease modifying anti-rheumatic drug (DMARD) treatment. Current evidence suggests that serum IgG4 levels are significantly elevated in RA compared to the general population. This review indicates that IgG4 is a promising biomarker of disease activity and tends to decline in response to DMARD therapies. Biologic therapies have revolutionized the therapeutic armamentarium of RA in the recent decade, and IgG4 appears to be a potential treatment target.

Keywords: arthritis; immune system; immunoglobulin G; rheumatoid.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The algorithm for the selection of studies in this systematic review.
Figure 2
Figure 2
Hypothetical pathogenesis model on the role of IgG4 in rheumatoid arthritis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Puissant-Lubrano B., Peres M., Apoil P.A., Congy-Jolivet N., Roubinet F., Blancher A. Immunoglobulin IgA, IgD, IgG, IgM and IgG subclass reference values in adults. Clin. Chem. Lab. Med. 2015;53:e359–e361. doi: 10.1515/cclm-2014-1186. - DOI - PubMed
    1. Corrigall V.M., Panayi G.S. Autoantigens and immune pathways in rheumatoid arthritis. Crit. Rev. Immunol. 2002;22:281–293. - PubMed
    1. Wang Y., Lu Q., Wu S.L., Karger B.L., Hancock W.S. Characterization and comparison of disulfide linkages and scrambling patterns in therapeutic monoclonal antibodies: Using LC-MS with electron transfer dissociation. Anal. Chem. 2011;83:3133–3140. doi: 10.1021/ac200128d. - DOI - PMC - PubMed
    1. Stone J.H., Khosroshahi A., Deshpande V., Chan J.K., Heathcote J.G., Aalberse R., Azumi A., Bloch D.B., Brugge W.R., Carruthers M.N., et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012;64:3061–3067. doi: 10.1002/art.34593. - DOI - PMC - PubMed
    1. Masaki Y., Dong L., Kurose N., Kitagawa K., Morikawa Y., Yamamoto M., Takahashi H., Shinomura Y., Imai K., Saeki T., et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: Analysis of 64 cases of IgG4-related disorders. Ann. Rheum. Dis. 2009;68:1310–1315. doi: 10.1136/ard.2008.089169. - DOI - PubMed